See more : Tacmina Corporation (6322.T) Income Statement Analysis – Financial Results
Complete financial analysis of SQI Diagnostics Inc. (SQIDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SQI Diagnostics Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- TopGum Industries Ltd. (TPGM.TA) Income Statement Analysis – Financial Results
- Thanapiriya Public Company Limited (TNP.BK) Income Statement Analysis – Financial Results
- Unitech Printed Circuit Board Corp. (2367.TW) Income Statement Analysis – Financial Results
- Signet Industries Limited (SIGNETIND.BO) Income Statement Analysis – Financial Results
- Terminalcare Support Institute Inc. (7362.T) Income Statement Analysis – Financial Results
SQI Diagnostics Inc. (SQIDF)
About SQI Diagnostics Inc.
SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. It also offers TOR-dx, a lung test, which enables the surgeon to assess the health of the donor's lung; and a COVID-19 at-home antibody test kit; the RALI-Dx, a COVID-19 severity triage lab test; and RALI-fast, a COVID-19 severity triage POC test. In addition, the company offers microarray instruments for antibody testing workflow. SQI Diagnostics Inc. was founded in 1999 and is headquartered in Toronto, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.10M | 917.00K | 1.02M | 1.89M | 1.34M | 968.00K | 1.42M | 443.00K | 119.00K | 3.00K | 12.00K | 36.00K | 35.00K | 31.94K | 89.84K | 71.55K | 20.00K | 15.38K |
| Cost of Revenue | 5.00M | 150.00K | 232.00K | 608.00K | 877.00K | 183.00K | 302.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.10M | 767.00K | 791.00K | 1.28M | 458.00K | 785.00K | 1.12M | 443.00K | 119.00K | 3.00K | 12.00K | 36.00K | 35.00K | 31.94K | 89.84K | 71.55K | 20.00K | 15.38K |
| Gross Profit Ratio | 38.30% | 83.64% | 77.32% | 67.85% | 34.31% | 81.10% | 78.75% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 7.28M | 7.58M | 3.78M | 4.53M | 3.95M | 3.14M | 3.43M | 3.54M | 3.42M | 3.86M | 3.89M | 5.46M | 5.06M | 3.36M | 2.03M | 1.85M | 0.00 | 0.00 |
| General & Administrative | 5.88M | 2.59M | 3.14M | 1.91M | 1.76M | 1.48M | 1.56M | 1.88M | 1.61M | 1.94M | 2.13M | 4.11M | 1.69M | 2.14M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 680.00K | 733.00K | 966.00K | 1.17M | 1.15M | 1.07M | 685.00K | 743.00K | 467.00K | 442.00K | 288.00K | 448.00K | 474.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.56M | 3.32M | 4.11M | 3.09M | 2.91M | 2.55M | 2.25M | 2.62M | 2.08M | 2.38M | 2.42M | 4.56M | 2.16M | 2.14M | 1.44M | 969.53K | 95.00K | 61.80K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 16.96M | 10.81M | 8.68M | 8.65M | 7.32M | 6.19M | 5.68M | 6.16M | 5.49M | 6.24M | 6.31M | 10.59M | 8.14M | 6.02M | 3.95M | 3.09M | 95.00K | 61.80K |
| Cost & Expenses | 21.95M | 10.96M | 8.92M | 9.26M | 8.19M | 6.38M | 5.98M | 6.16M | 5.49M | 6.24M | 6.31M | 10.59M | 8.14M | 6.02M | 3.95M | 3.09M | 95.00K | 61.80K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.00K | 20.00K | 25.00K | 11.00K | 61.00K | 32.00K | 121.18K | 73.34K | 64.54K | 20.00K | 15.38K |
| Interest Expense | 2.60M | 518.00K | 679.00K | 656.00K | 579.00K | 521.00K | 483.00K | 303.00K | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 45.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.81M | 753.00K | 800.00K | 500.00K | 460.00K | 499.00K | 536.00K | 551.00K | 652.00K | 669.00K | 635.00K | 578.00K | 515.00K | 514.76K | 476.92K | 273.55K | 0.00 | 0.00 |
| EBITDA | -10.05M | -9.29M | -7.09M | -6.87M | -6.61M | -5.14M | -4.38M | -5.17M | -4.72M | -5.56M | -5.64M | -9.98M | -7.59M | -5.47M | -3.38M | -2.75M | -74.99K | -46.42K |
| EBITDA Ratio | -123.99% | -1,012.65% | -693.26% | -363.04% | -479.25% | -507.13% | -282.90% | -1,163.88% | -3,878.99% | -185,433.33% | -46,975.00% | -27,719.44% | -21,674.29% | -17,128.59% | -3,764.56% | -3,840.49% | -374.89% | -301.75% |
| Operating Income | -19.56M | -10.04M | -7.89M | -7.37M | -6.86M | -5.41M | -4.56M | -6.02M | -5.37M | -6.23M | -6.30M | -10.56M | -8.10M | -5.99M | -3.86M | -3.02M | -74.99K | -46.42K |
| Operating Income Ratio | -241.42% | -1,094.77% | -771.46% | -389.48% | -513.71% | -558.68% | -320.62% | -1,359.14% | -4,515.97% | -207,733.33% | -52,475.00% | -29,325.00% | -23,145.71% | -18,740.19% | -4,295.42% | -4,222.81% | -374.89% | -301.75% |
| Total Other Income/Expenses | 1.04M | -518.00K | -539.00K | -411.00K | -369.00K | -292.00K | -123.00K | -76.00K | -86.00K | 25.00K | -14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -18.52M | -10.56M | -8.57M | -8.02M | -7.44M | -5.93M | -5.04M | -6.10M | -5.46M | -6.21M | -6.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -228.62% | -1,151.25% | -837.83% | -424.17% | -557.08% | -612.50% | -354.61% | -1,376.30% | -4,588.24% | -206,900.00% | -52,591.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.60M | -187.00K | -1.08M | -245.00K | -210.00K | -229.00K | -360.00K | 303.00K | 86.00K | 0.00 | 14.00K | 190.00K | -28.00K | -75.83K | -73.34K | -64.54K | 74.99K | 46.42K |
| Net Income | -18.52M | -10.56M | -8.57M | -8.02M | -7.44M | -5.93M | -5.04M | -6.10M | -5.46M | -6.21M | -6.31M | -10.75M | -8.07M | -5.91M | -3.79M | -2.96M | -74.99K | -46.42K |
| Net Income Ratio | -228.62% | -1,151.25% | -837.83% | -424.17% | -557.08% | -612.50% | -354.61% | -1,376.30% | -4,588.24% | -206,900.00% | -52,591.67% | -29,852.78% | -23,065.71% | -18,502.79% | -4,213.78% | -4,132.61% | -374.89% | -301.75% |
| EPS | -0.05 | -0.03 | -0.03 | -0.05 | -0.06 | -0.06 | -0.07 | -0.11 | -0.11 | -0.15 | -0.17 | -0.32 | -0.27 | -0.23 | -0.18 | -0.18 | -0.01 | -0.01 |
| EPS Diluted | -0.05 | -0.03 | -0.03 | -0.05 | -0.06 | -0.06 | -0.07 | -0.11 | -0.11 | -0.15 | -0.17 | -0.32 | -0.27 | -0.23 | -0.18 | -0.18 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 389.72M | 338.45M | 266.94M | 178.39M | 130.97M | 93.81M | 69.23M | 57.48M | 50.98M | 41.96M | 37.41M | 33.87M | 30.35M | 25.16M | 20.55M | 16.62M | 8.00M | 7.76M |
| Weighted Avg Shares Out (Dil) | 389.72M | 338.45M | 266.94M | 178.39M | 130.97M | 93.81M | 69.23M | 57.48M | 50.98M | 41.96M | 37.41M | 33.87M | 30.35M | 25.16M | 20.55M | 16.62M | 8.00M | 7.76M |
SQI Diagnostics Appoints Andrew Morris as Chief Executive Officer, and Grants Options
TORONTO, Sept. 13, 2021 /PRNewswire/ - SQI Diagnostics, Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that the Company's...
SQI Diagnostics Inc. Announces Grant of Stock Options
TORONTO , Aug. 30, 2021 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective...
SQI Diagnostics Reports Third Quarter 2021 Results
TORONTO, Aug. 18, 2021 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today reported its financial and operational results for...
FDA Stops Emergency Use Authorization Review of SQI Diagnostics RALI-Dx™ IL-6 Severity Triage Test for COVID-19 Patients
FDA cites de-prioritization due to high volume of EUA reviews; recommends other approval pathway for this test TORONTO, July 23, 2021 /PRNewswire/ - SQI Diagnostics Inc. (the "Company" or "SQI") (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers,...
SQI Diagnostics and AZOVA sign distribution agreement to sell SQI's COVID-19 HOME Antibody Test
TORONTO, July 15, 2021 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI") and AZOVA Inc., creator of the world's most comprehensive...
SQI Diagnostics Inc. Announces $3.9 Million Funding via Warrant Exercise by Insiders
TORONTO, June 15, 2021 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics today announces that certain insiders of...
SQI Diagnostics Inc. Announces Grant of Stock Options
TORONTO, May 27, 2021 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective May 27,...
SQI Diagnostics Reports Second Quarter 2021 Results and Announces Departure of CEO and Appointment of Interim CEO
TORONTO, May 21, 2021 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, announced today that...
SQI Diagnostics Submits RALI-Dx™ IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization
Test Designed to Assist in Identifying Severe Inflammatory Response in Patients with Confirmed COVID-19 Illness TORONTO, April 1, 2021 /PRNewswire/ - SQI Diagnostics Inc. (the "Company" or "SQI") (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and...
SQI Diagnostics Reports First Quarter 2021 Results
TORONTO, March 1, 2021 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today reported its financial...
Source: https://incomestatements.info
Category: Stock Reports